Yes, MANF has been shown to be superior to GDNF in

Yes, MANF has been shown to be superior to GDNF in the lab. AND, GDNF is currently in clinical trials for PD. Just think what MANF might do for the fellow you posted about. MANF does appear to be a "miracle molecule".

Quote:

---

Amarantus BioScience Announces Positive Efficacy Data for MANF in a Nigral Delivery Neurorestoration Animal Model of Parkinson's Disease

SUNNYVALE, Calif., Jan. 9, 2013

The data demonstrate that unlike Glial cell-Derived Neurotrophic Factor (GDNF), MANF significantly reduces behavioral deficits, increases dopaminergic (DA) nerve terminal reinnervation of the striatum, and increases dopamine concentrations in the striatum when MANF is administered directly to the substantia nigra (SNc). GDNF is an agent currently in clinical trials for Parkinson's disease. Dr. John W. Commissiong, Chief Scientific Officer of Amarantus,

"Today's data support previously reported behavioral data where MANF demonstrated superiority over GDNF," said Dr. John W. Commissiong. "Going forward, the Company is in a strong position to advance MANF as a potential disease-modifying treatment for Parkinson's based on unique behavioral, morphological and neurochemical data in standard animal models of the disease."

The data produced comparing optimal doses to the SNc of MANF = 10 ug and GDNF = 10 ug in this model indicate the following at four weeks post-treatment:
1.MANF reduced behavioral deficits by 53%, whereas behavioral deficits with GDNF increased by 20%;
2.MANF produced a 14.4% reinnervation of the striatum, whereas striatum innervation with GDNF was reduced by 9.9%;
3.MANF increased dopamine concentrations in the striatum, whereas striatum dopamine concentrations with GDNF did not increase.

"We are excited about our results with MANF as we have demonstrated superiority to GDNF in a number of key areas related to recovery of function in Parkinson's disease," added Dr. Joseph Rubinfeld, Amarantus advisor and Amgen Co-Founder. "We intend to continue to move our Parkinson's program forward, while also evaluating other disease indications for MANF with potentially accelerated regulatory pathways, including certain orphan diseases. This strategy may significantly reduce MANF's overall time to market versus a Parkinson's-only strategy."

---

Welcome Cards. A medical student would be a great asset to this board.

GO AMBS